Researchers associated increased blood p-tau181 levels with cognitive decline and neurodegeneration in Alzheimer's disease-characteristic brain areas among individuals with elevated amyloid-beta levels, while higher plasma neurofilament light chain levels correlated with cognitive impairment and neurodegeneration among those with and without amyloid-beta accumulation, researchers reported in JAMA Neurology. The study "is a major step forward showing that blood tests for tau pathology and neurodegeneration have clinical value to track disease progression in patients with Alzheimer's disease," said researcher Dr. Kaj Blennow.
Blood biomarkers tied to Alzheimer's progression
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.